恶性肿瘤患者术中自体血回输的临床应用进展

doi:10.20047/j.issn1673-7210.2023.12.10

Abstract
Figure/Table
References (39)
Related Citation (15)

Download: PDF (509 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract With the aggravation of the aging population in China, the incidence rate of malignant tumors remains high. More and more patients with malignant tumors choose surgical treatment, which makes the clinical blood demand increase day by day. In order to relieve the pressure of clinical blood use, various blood protection methods emerge in endlessly. Intra- operative cell salvage (IOCS) is one of the most widely used and cost-effective methods in recent years. It has been listed as a routine measure in major operations such as heart and trauma. Malignant tumors usually have extensive blood supply, large surgical trauma and a large amount of bleeding. Allogeneic blood transfusion is often needed to ensure the safety of patients, but allogeneic blood transfusion is not conducive to the prognosis of patients. Therefore, in recent years, the application of IOCS technology in patients with malignant tumors has been reported, especially the application of combined leukocyte-depleted filter is increasing. This paper reviews the current situation of IOCS in patients with malignant tumors through literature review.

Key words： Tumor Intra- operative cell salvage Clinical application Progress

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WANG Donghong1 ZHAO Yongqiang2 LI Wenjuan1 XUE Jianjun3

Cite this article:

WANG Donghong1 ZHAO Yongqiang2 LI Wenjuan1 XUE Jianjun3. Progress in clinical application of intra-operative cell salvage in patients with malignant tumors[J]. 中国医药导报, 2023, 20(12): 48-51.

URL:

https://www.yiyaodaobao.com.cn/EN/10.20047/j.issn1673-7210.2023.12.10 OR https://www.yiyaodaobao.com.cn/EN/Y2023/V20/I12/48

[1] 刘宗超，李哲轩，张阳，等.2020全球癌症统计报告解读[J].肿瘤综合治疗电子杂志，2021，7（2）：1-13．
[2] Feng RM，Zong YN，Cao SM，et al. Current cancer situation in China：good or bad news from the 2018 Global Cancer Statistics? [J]. Cancer Commun（Lond），2019，39（1）：12.
[3] Kumar N，Zaw AS，Khoo BL，et al. Intraoperative cell salvage in metastatic spine tumour surgery reduces potential for reinfusion of viable cancer cells[J]. Eur Spine J，2016，25（12）：4008-4015．
[4] Karczewski DM，Lema MJ，Glaves D. The efficiency of anauto-transfusion system for tumor cell removal from blood salvaged during cancer surgery [J]. Anesth Analg，1994，78（6）：1131-1135.
[5] Wu WW，Zhang WY，Zhang WH，et al. Survival analysis of intraoperative blood salvage for patients with malignancy disease：A PRISMA-compliant systematic review and meta-analysis [J]. Medicine，2019，98（27）：1-7.
[6] Foltys D，Zimmermann T，Heise M，et al. Liver Transplantation for Hepatocellular Carcinoma-Is There a Risk of Recurrence Caused by Intraoperative Blood Salvage Autotransfusion? [J]. Eur Surg Res，2011，47（3）：182-187.
[7] 李振洲，陈雅儒，郭建荣.回收式自体输血在恶性肿瘤患者手术中的应用及风险评估[J]. 中国输血杂志，2022，35（3）：345-348.
[8] Araujo RL，Pantanali CA，Haddad L，et al. Does autologous blood transfusion during liver transplantation for hepatocellular carcinoma increase risk of recurrence? [J]. World J Gastrointest Surg，2016，8（2）：161-168.
[9] Han S，Kim G，Ko JS，et al. Safety of the Use of Blood Salvage and Autotransfusion During Liver Transplantation for Hepatocellular Carcinoma [J]. Ann Surg，2016，264（2）：339-343.
[10] Kim JM，Kim GS，Joh JW，et al. Long-term results for living donor liver transplant recipients with hepatocellular carcinoma using intraoperative blood salvage with leukocyte depletion filter [J]. Transpl Int，2013，26（1）：84-89.
[11] Pinto MA，Tomaz JM，Grezzana-Filho TJM，et al. Impact of intraoperative blood salvage and autologous transfusion during liver transplantation for hepatocellular carcinoma [J]. Langenbeck Arch Surg，2021，406（1）：67-74.
[12] Xing YL，Wang YC. Influence of Autologous and Homologous Blood Transfusion on Interleukins and Tumor Necrosis Factor-α in Peri-operative Patients with Esophageal Cancer [J]. Asian Pac J Cancer Prev，2014，15（18）：7831- 7834.
[13] Gong Y，Tang Y，Xue Y，et al. Impact of intraoperative allogenic and autologous transfusion on immune function and prognosis in patients with hepatocellular carcinoma [J]. Medicine，2020，99（41）：1-6
[14] 黄晶，付佳.肿瘤患者围手术期自异体输血对输血相关免疫调节效应影响的比较[J].沈阳医学院学报，2020， 22（3）：231-234.
[15] 李佳丽.肿瘤患者自异体输血对输血免疫功能、IL-10及IFN-γ水平的影响[J].临床研究，2021，29（8）：21-23.
[16] 袁莉，闫伟华，饶伟，等.肿瘤患者肝移植术中回收自体血细胞形态及病理学研究[J].实用器官移植电子杂志，2016，4（4）：226-230.
[17] 王文秀，段声吉，杨晓茂，等.骨科手术中自体血回输的临床效果[J].西南医科大学学报，2022，45（2）：127-130.
[18] 聂桑，黎浪，蔡宏伟.71例儿童骨科患者应用自体血回输的回顾性分析[J].中国医学工程，2019，27（6）：68-72.
[19] 安玉玲，李文娟，安成强，等.老年全髋关节置换术中应用自体血回输的回顾性研究[J].中国实用医药，2022， 17（10）：63-66. .
[20] Chen Y，Tai BC，Nayak D，et al. Blood loss in spinal tumour surgery and surgery for metastatic spinal disease：a meta-analysis [J]. Bone Joint J，2013，95（5）：683-688.
[21] 张闻力，毕文志，董扬，等.中国骨肿瘤大手术加速康复围手术期管理专家共识[J].中华骨与关节外科杂志，2019， 12（5）：321-327.
[22] 朱姝颖，唐育民，张宏伟，等.血液回收自体输血用于肿瘤大手术的研究进展[J].中国输血杂志，2015，28（4）：466-469.
[23] Kumar N，Ahmed Q，Lee VK，et al. Are we ready for the use of intraoperative salvaged blood in metastatic spine tumour surgery? [J]. Eur Spine J，2016，25（12）：3997-4007.
[24] 尚玉，邵小宝，周琳，等.白细胞滤器去除血液肿瘤细胞的实验研究[J].中国输血杂志，2021，34（5）：452-455.
[25] Elmalky M，Yasin N，Rodrigues-Pinto R，et al. The safety，efficacy and cost-effectiveness of intraoperative cell-salvage in metastatic spine tumour surgery [J]. Spine J，2017， 17（7）：977-982.
[26] Kumar N，Lam R，Zaw AS，et al. Flow Cytometric Evaluation of the Safety of Intraoperative Salvaged Blood Filtered with Leucocyte Depletion Filter in Spine Tumour Surgery [J]. Ann Surg Oncol，2014，21（13）：4330-4335.
[27] Jemal A，Siegel R，Xu J，et al. Ward E（2010）Cancer statistics [J]. CA Cancer J Clin ，2011，60（5）：277-300.
[28] Gorin MA，Eldefrawy AM，Manoharan M，et al. Oncologic outcomes following radical prostatectomy with intraoperative cell salvage [J]. World J Urol，2012，30（3）：379-383 .
[29] Nieder AM，Carmack AJ，Sved PD，et al. Intraoperative cell salvage during radical prostatectomy is not associated with greater biochemical recurrence rate [J]. Urology ，2005，65（4）：730-734.
[30] Li SL，Ye Y，Yuan XH. Association between Allogeneic or Autologous Blood Transfusion and Survival in Patients after Radical Prostatectomy：A Systematic Review and Meta- Analysis [J]. PLoS One，2017，12（1）：1-11.
[31] Catling S，Williams S，Freites O，et al. Use of a leucocyte filter to remove tumour cells from intraoperative cell salvage blood [J]. Anaesthesia，2008，63（12）：1332-1338.
[32] Galaal K，Lopes A，Pritchard C，et al. Trial of intraoperative cell salvage versus transfusion in ovarian cancer（TIC TOC）：protocol for a randomised controlled feasibility study [J]. BMJ Open，2018，8（11）：1-9.
[33] 张小青，曾鸿.回收式自体输血与白细胞滤器在恶性肿瘤术中应用的研究进展[J].中国微创外科杂志，2021， 21（1）：69-72.
[34] 邵长会，张董瑜，欧珊，等.术中血液回收技术研究进展[J].麻醉安全与质控，2019，3（6）：357-361.
[35] Allan AL，Keeney M. Circulating tumor cell analysis：technical and statistical considerations for application to the clinic [J]. J Oncol，2010，2010：426218.
[36] Kumar N，Zaw AS，Kantharajanna SB，et al. Metastatic efficiency of tumour cells can be impaired by intraoperative cell salvage process：truth or conjecture? [J]. Transfus Med，2017，27（5）：327-334.
[37] 张娜，魏伟，许新科，等.回收式自体输血联合白细胞滤器在小儿脑肿瘤切除术中的应用[J]. 实用医学杂志，2022， 38（7）：873-878.
[38] Kumar N，Zaw AS，Khoo BL，et al. Intraoperative cell salvage in metastatic spine tumour surgery reduces potential for reinfusion of viable cancer cells [J]. Eur Spine J，2016， 25（12）：4008-4015.
[39] 张斌，许川雅.回收式自体血回输在外科恶性肿瘤手术中的应用现状[J].中国微创外科杂志，2020，20（4）：366- 368.